The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
The month saw the first commissioner's priority voucher approval in oncology.
But biomarker enrichment and toxicity remain key for FX-909.
Welireg looks headed to regulators in second-line and adjuvant kidney cancer.
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
The company will license EGFR and cMet inhibitors from Celyn.
TARA-002 goes from looking better than Inlexzo to seeming rather worse.
